Senators Bernie Sanders and Angus King have introduced the End Prescription Drug Ads Now Act, a legislative proposal aimed at banning prescription drug advertising across various media platforms. This move aligns with Health and Human Services Secretary Robert F. Kennedy Jr.’s advocacy against such advertisements during his 2024 presidential campaign for President Trump.
Sanders criticized pharmaceutical companies for their substantial spending on television commercials promoting expensive drugs. “The American people are sick and tired of greedy pharmaceutical companies spending billions of dollars on absurd TV commercials pushing their outrageously expensive prescription drugs,” he stated. He highlighted that the United States, alongside New Zealand, is one of the few countries allowing this practice.
King echoed these sentiments, emphasizing the impact of direct-to-consumer advertising on healthcare costs without necessarily improving patient health outcomes. “The widespread use of direct-to-consumer advertising by pharmaceutical companies drives up costs and doesn’t necessarily make patients healthier,” King said.
The bill’s introduction comes amid reports that major drug companies earned over $100 billion in profits last year while spending more than $5 billion on television ads. These advertisements constitute a significant portion of commercial airtime during evening news programs on major networks.
Proponents argue that banning such ads is not unprecedented; it has been supported by figures like Secretary Kennedy and organizations like the American Medical Association. Studies indicate that many prescription drug ads are misleading, often downplaying risks associated with medications.
Historically, pharmaceutical firms have invested heavily in marketing specific drugs despite safety concerns or questionable efficacy compared to existing treatments. Examples include Eli Lilly’s Cymbalta and Merck’s Vioxx, both marketed aggressively despite findings of misleading claims or serious health risks.
Furthermore, disparities in drug pricing between the U.S. and other countries have been noted, with Americans paying significantly higher prices for certain medications marketed through direct-to-consumer ads.
Joining Sanders and King as cosponsors are Senators Chris Murphy, Peter Welch, Jeff Merkley, and Dick Durbin.
